Rockefeller Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Rockefeller Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$629K	Sell	3,722 -3,731	-50%	-$644K	﹤0.01%	1841
2025 Q4	$1.36M	Buy	7,453 +1,716	+30%	+$240K	﹤0.01%	1414
2025 Q3	$697K	Buy	+5,737	New	+$646K	﹤0.01%	1611
2023 Q1	–	Sell	-350	Closed	-$27K	–	2127
2022 Q4	$27K	Hold	350	–	–	﹤0.01%	2675
2022 Q3	$15K	Hold	350	–	–	﹤0.01%	2890
2022 Q2	$13K	Hold	350	–	–	﹤0.01%	2973
2022 Q1	$14K	Hold	350	–	–	﹤0.01%	2876
2021 Q4	$13K	Hold	350	–	–	﹤0.01%	2831
2021 Q3	$11K	Hold	350	–	–	﹤0.01%	2833
2021 Q2	$23K	Hold	350	–	–	﹤0.01%	2418
2021 Q1	$19K	Hold	350	–	–	﹤0.01%	2295
2020 Q4	$28K	Sell	350 -2,000	-85%	-$150K	﹤0.01%	1872
2020 Q3	$167K	Hold	2,350	–	–	﹤0.01%	1101
2020 Q2	$193K	Hold	2,350	–	–	﹤0.01%	960
2020 Q1	$138K	Buy	+2,350	New	+$191K	﹤0.01%	917

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rockefeller Capital Management's AXSM Position: Q1 2026 in Review

Rockefeller Capital Management reduced its Axsome Therapeutics (AXSM) stake by 50% in Q1 2026, selling an estimated $644K and leaving 3,722 shares worth $629K. The position accounts for ﹤0.01% of the portfolio, ranked #1841.

Rockefeller Capital Management first reported a position in AXSM in Q1 2020 and has held it in 15 quarters since. The position peaked at $1.36M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Rockefeller Capital Management held 3,722 shares of Axsome Therapeutics worth $629K as of Q1 2026.
Rockefeller Capital Management sold 3,731 Axsome Therapeutics shares in Q1 2026, an estimated $644K.
Axsome Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #1841 holding.
Rockefeller Capital Management first reported a position in Axsome Therapeutics in Q1 2020 and has held it in 15 quarters since.
Rockefeller Capital Management's Axsome Therapeutics position peaked at $1.36M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.